No price com­pe­ti­tion in PD-(L)1? That might not last long as EQRx, CStone read out late-stage win for chal­lenger

Drug pric­ing dis­rup­tor EQRx has made a show about its mis­sion to ag­gres­sive­ly dis­count drug mar­kets dom­i­nat­ed by ex­pen­sive med­i­cines with no mean­ing­ful price com­pe­ti­tion. One of the most ob­vi­ous tar­gets is PD-(L)1, and now one of EQRx’s part­nered drugs is get­ting its af­fairs in or­der for a late mar­ket en­try.

EQRx and CStone’s sug­e­mal­imab hit its pri­ma­ry end­point of pro­gres­sion-free sur­vival as a con­sol­i­da­tion ther­a­py for pa­tients with stage III non-small cell lung can­cer whose dis­ease hasn’t pro­gressed af­ter con­cur­rent or se­quen­tial chemora­dio­ther­a­py, the com­pa­ny said Fri­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER